THE USE OF PCSK9-TARGETED THERAPY IN PATIENTS WITH CORONARY HEART DISEASE AND AORTIC VALVE STENOSIS AFTER SURGERY (CLINICAL EXAMPLES OF AN EXPLORATORY RESEARCH STUDY)

Highlights The relevance of the clinical case is related to the high incidence of Fallot's tetrad and the need for complex cardiac surgery, including prosthetics of the excretory right ventricle. The development and application of high-quality conduits, such as Pylon, is important for improving surgical outcomes in children. Abstract In this paper, using clinical examples of two patients from an exploratory scientific study with an established diagnosis of coronary heart disease and operated aortic valve stenosis, an analysis of the efficacy and safety of using a PCSK9 inhibitor (alirocumab) as part of a combination lipid-lowering therapy prescribed for the correction of dyslipidemia over 4 months of treatment is presented. It is shown that over 4 months of the exploratory scientific study, despite the high safety of the prescribed treatment, the reduction in low-density lipoprotein cholesterol in this category of patients remains suboptimal and is not accompanied by the achievement of its target values, which justifies the need for additional optimization of lipidological treatment as part of cardiovascular risk management.